Autoantibodies
7
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Standardized Italian netwoRk Enrolling iNdividuals With Islet-Autoantibodies
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
Follow-up Study of Individuals with Autoantibodies Against Ro/SSA and La/SSB
TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
Characterization of Natural IL-6 Inhibition in Healthy Individuals
The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor
Thyroid Autoimmunity and Reproductive Failure in Danish Women